Høgestøl EA, Brustad ÅW, Celius EG, Meling M, Berg-Hansen P, Kro GB, König M, Schanke Y, Halvorsen B, Warren DJ, Gehin JE, Bolstad N, Nygaard GO (2026)
Serum drug levels and JCV assay discrepancies after switching from originator to biosimilar natalizumab
BMJ Neurol Open, 8 (1), e001477
DOI 10.1136/bmjno-2025-001477, PubMed 41877736

Holly T, Kirkesaether Brun M, Jørgensen KK, Goll GL, Sexton J, Gehin JE, Kvien TK, Jahnsen J, Provan SA, Bolstad N, Aas E, Haavardsholm EA, Kristiansen IS, Syversen SW, Hagen G (2026)
Cost-effectiveness of proactive therapeutic drug monitoring of maintenance infliximab treatment in patients with immune-mediated inflammatory diseases: results from a randomised controlled trial
RMD Open, 12 (1)
DOI 10.1136/rmdopen-2025-006329, PubMed 41856561

Gehin JE, Klaasen RA, Kristianslund EK, Jyssum I, Sexton J, Warren DJ, Aletaha D, Haavardsholm EA, Goll GL, Syversen SW, Bolstad N (2026)
The Effect of Certolizumab Pegol Dose and Dose Changes on Plasma Trough Levels: Data From a Randomized Phase III Trial
Ther Drug Monit (in press)
DOI 10.1097/FTD.0000000000001440, PubMed 41622540